drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting GPRC5D, a GPCR highly expressed on plasma cells, to drive antigen-specific T-cell cytotoxicity against malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a chimeric antigen receptor that recognizes GPRC5D on plasma cells; antigen binding triggers CAR signaling (CD3ΞΆ with costimulatory domains) to activate T-cell cytotoxicity, cytokine release, and clonal expansion, leading to targeted lysis of GPRC5D-expressing malignant plasma cells.
drug_name
GPRC5D-directed CAR-T cells
nct_id_drug_ref
NCT06429150